Please assess the completion status of the following clinical trial:

Trial Title: Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients must meet all of the following criteria to be eligible for inclusion in the study:~1. Patients with confirmed diagnosis of Ulcerative Colitis or Crohn's Disease.~2. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.~3. Patient eligible to receive INFLECTRA for the treatment of their disease per approved drug label (patients with fistula, or stoma are eligible).~Exclusion Criteria:~-Patients meeting any of the following criteria will not be included in the study:~1. Patient previously failed treatment with REMICADE or INFLECTRA/CT P13.~2. Any reported contraindications for INFLECTRA/CT P13 or REMICADE.~3. Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ulcerative Colitis (Type: None): Group treated with Inflectra for Ulcerative Colitis
- Crohn's Disease (Type: None): Group treated with Inflectra for Crohn's Disease

Based on this trial design, predict the completion outcome and termination type (if applicable).